School of Medicine
Showing 1-9 of 9 Results
Norman J. Lacayo, MD
Associate Professor of Pediatrics (Hematology and Oncology)
Current Research and Scholarly InterestsPediatric Hematology/Oncology, Phase I drug studies for refractory and relapsed leukemia; genomic studies, biologic risk-stratification and treatment of acute myeloid leukemia; prediction or induction response and risk of relapse using phosphoproteomics in childhood AML; novel MRD techniques in childhood ALL.
Lydia J. Lee Professor of Pediatric Cancer
Current Research and Scholarly InterestsHematology/Oncology, treatment of sarcomas of bone and soft tissue, biology of acute lymphoblastic leukemias, treatment of non-Hodgkin's lymphoma and Hodgkin's disease.
Research Data Analyst, Pediatrics - Hematology/Oncology
BioMy primary research interest are in the development and application of computational approaches to drug discovery, drug design and target prediction. I have pioneered new computational approaches to determine drug actions based on chemical networks (https://services.mbi.ucla.edu/CSNAP/) and applied this method to discover new drugs inhibiting cell divisions and cancers. My current research at the Altman's lab focuses on developing novel computational methods for predicting drug actions, interactions, side-effects and drug repurposing. By correlating low-level structural data with high-level functional biology and clinical outcomes, I will apply system-based approach to engineer safe and effective medicine for disease treatments.
Clinical Associate Professor, Pediatrics - Hematology & Oncology
Current Research and Scholarly InterestsResearch interests include:
Biomarkers and targeted therapy in pediatric immune thrombocytopenia
Transfusion-related iron overload
Hemophilia and other rare bleeding disorders
Adrienne H. Long, MD, PhD
Postdoctoral Medical Fellow, Hematology-Oncology
Fellow in Pediatrics - Hematology & Oncology
BioAdrienne H. Long, MD, PhD is a fellow in the Division of Pediatric Hematology and Oncology at the Lucile Packard Children's Hospital at Stanford. Dr. Long attend Northwestern University, where she earned both her BS in biomedical engineering and her MD. Determined to help develop novel treatments for pediatric cancer patients, she took time during medical school to pursue a PhD at the National Institutes of Health (NIH), where she helped advance CAR T cell therapies with Dr. Crystal Mackall. Her influential thesis work was the first to identify T cell exhaustion as a critical factor limiting efficacy of CAR therapies (Long et al., Nature Medicine, 2015), and also identified novel methods to enhance CAR therapies for pediatric solid tumor patients (Long/Highfill et al., Cancer Immunology Research, 2016). Dr. Long went on to complete her pediatrics residency training at Boston Children’s Hospital, where she continued her research in cancer immunology with Dr. Nicholas Haining – this time focusing on strategies to enhance antigen presentation to augment checkpoint blockade (Long et al. Keystone Symposium on Cancer Immunotherapy, 2019). She remains dedicated to a career as a physician-scientist focused on developing novel immunotherapies for children with cancer.